Safety and tolerability of extended efalizumab therapy in patients with chronic moderate to severe plaque psoriasis

被引：0

作者：

Gottlieb, A

Hamilton, T

Rafal, E

Caro, I

机构：

[1] UMDNJ Robert Wood Johnson Med Sch, Clin Res Ctr, New Brunswick, NJ USA

[2] Atlanta Dermatol, Vein & Res Ctr, Alpharetta, GA USA

[3] DermRes Ctr New York Inc, Stony Brook, NY USA

[4] Genentech Inc, San Francisco, CA 94080 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2006年 / 54卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：AB11 / AB11

页数：1

共 50 条

[1] Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis
Leonardi, C
Goffe, B
Sobell, J
Caro, I
Wang, X
Papp, K
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A58 - A58
[2] Safety and efficacy of efalizumab therapy for elderly patients with moderate to severe chronic plaque psoriasis
Gottlieb, A
Lizzul, P
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P194 - P194
[3] Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis
Papp, KA
Miller, B
Gordon, KB
Caro, I
Kwon, P
Compton, PG
Leonardi, CL
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (04) : S164 - S170
[4] Safety and tolerability of efalizumab therapy for patients with moderate to severe chronic plaque psoriasis: Results of an open-label phase IIIB multicenter trial
Menter, A
Hamilton, T
Papp, K
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P195 - P195
[5] Efficacy and safety outcomes of long-term efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: an update
Gottlieb, AB
Hamilton, T
Caro, I
Gordon, K
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A57 - A57
[6] Safety and tolerability of efalizumab therapy: 60 weeks results from a phase IIIb trial in moderate-to-severe plaque patients with psoriasis
Menter, A
BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (01)
[7] Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis
Menter, A
Gordon, K
Carey, W
Hamilton, T
Glazer, S
Caro, I
Li, N
Gulliver, W
ARCHIVES OF DERMATOLOGY, 2005, 141 (01) : 31 - 38
[8] The safety of efalizumab in patients with moderate to severe plaque psoriasis: Summary of clinical trial experience
Leonardi, C
Goffe, B
Sobell, J
Caro, I
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P157 - P157
[9] Efalizumab for the treatment of moderate to severe plaque psoriasis
Jordan, JK
ANNALS OF PHARMACOTHERAPY, 2005, 39 (09) : 1476 - 1482
[10] Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: Review of clinical data. Part II
Papp, Kim A.
Camisa, Charles
Stone, Stephen P.
Caro, Ivor
Wang, Xiaolin
Compton, Peter
Walicke, Patricia A.
Gottlieb, Alice B.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2005, 9 (06) : 313 - 323

← 1 2 3 4 5 →